| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453921 | Lung Cancer | 2018 | 7 Pages |
Abstract
Administration of 4 courses of pemetrexed/carboplatin was feasible. The efficacy was similar to neoadjuvant regimens previously investigated. A significant number of patients 19 of 46 (41%) in this trial did not have surgical resection after neoadjuvant therapy. Further investigation of the role of neoadjuvant pemetrexed/carboplatin requires a larger, randomized clinical trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
John D. Hainsworth, David M. Waterhouse, Kent C. Shih, Ralph V. Boccia, Victor M. Priego, Michael J. McCleod, Fred J. Kudrik, Reed Brian Mitchell, Howard A. III, F. Anthony Greco, David R. Spigel,